In addition, the paclitaxel coating was shown to reduce the restenosis rate by 53% in a head-to-head comparison of provisional paclitaxel-eluting versus bare metal stent placement.
Michael Dake, professor in the Department of Cardiothoracic Surgery at Stanford University Medical School and medical director of the Cath/Angio Laboratories at Stanford University Medical Center, California, USA, principal investigator for the Zilver PTX trial, presented the study findings at the Vascular Interventional Advances (VIVA) 2012 (Las Vegas, USA, 9–12 October 2012)
Zilver PTX is neither approved by the FDA nor available for sale in the United States.
